Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
126.00
0.00 (0.00%)
Apr 28, 2026, 1:30 PM CST
-19.75%
Market Cap 21.10B
Revenue (ttm) 35.83M
Net Income (ttm) -340.54M
Shares Out 167.49M
EPS (ttm) -2.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 118,815
Average Volume 200,094
Open 123.00
Previous Close 126.00
Day's Range 123.00 - 126.50
52-Week Range 121.00 - 329.50
Beta 0.22
RSI 31.04
Earnings Date May 11, 2026

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders; and CS028, which is in the pre-clinical stage for the treatment of solid tumors. In addition, the compa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 39
Stock Exchange Taipei Exchange
Ticker Symbol 6535
Full Company Profile

Financial Performance

In 2025, Lumosa Therapeutics's revenue was 35.83 million, a decrease of -8.49% compared to the previous year's 39.15 million. Losses were -340.54 million, -19.83% less than in 2024.

Financial Statements

News

There is no news available yet.